Drug Profile
Leuprorelin - Pierre Fabre
Alternative Names: CI-18; OnectylLatest Information Update: 18 Nov 2021
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 23 Oct 2008 Phase III development is ongoing in European Union
- 07 Jul 2005 Phase-III clinical trials in Prostate cancer in European Union (SC)
- 07 Aug 2004 Phase-II clinical trials in Prostate cancer in European Union (SC)